TY - JOUR
T1 - Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection
AU - Malhotra, Uma
AU - Berrey, M. Michelle
AU - Huang, Yijian
AU - Markee, Janan
AU - Brown, Darin J.
AU - Ap, Sophe
AU - Musey, Luwy
AU - Schacker, Timothy
AU - Corey, Lawrence
AU - McElrath, M. Juliana
N1 - Funding Information:
Grant support: National Institutes of Health (AI45206, AI01550, AI38858, and AI41535).
PY - 2000
Y1 - 2000
N2 - T-cell responses were evaluated prospectively in 41 patients with acute human immunodeficiency virus type 1 (HIV-1) infection (30 untreated and 11 receiving zidovudine, lamivudine, and indinavir) and in 38 uninfected adults. By 6-12 months, treated patients had significantly greater median Candida and tetanus lymphoproliferative responses (stimulation index [SI], 76 and 55, respectively) than did untreated patients (SI, 7 and 6, P = .02 and .001, respectively), and the responses of treated patients surpassed those of uninfected adults (SI, 19 and 32, P = .002 and .101, respectively). Unlike the patients in the untreated group, the patients in the treated group mounted a 6-fold increased HIV-1 p24 response (SI increase, 1.0 to 5.7, P = .01) within 3 months. HIV-1-specific cytotoxicity remained detectable in most treated patients. Thus, combination therapy administered within 3-4 months of infection was associated with improved T-cell memory responses that were distinct from those of untreated patients. The amplified HIV-1-specific T- cell responses may help maintain cytotoxic activities.
AB - T-cell responses were evaluated prospectively in 41 patients with acute human immunodeficiency virus type 1 (HIV-1) infection (30 untreated and 11 receiving zidovudine, lamivudine, and indinavir) and in 38 uninfected adults. By 6-12 months, treated patients had significantly greater median Candida and tetanus lymphoproliferative responses (stimulation index [SI], 76 and 55, respectively) than did untreated patients (SI, 7 and 6, P = .02 and .001, respectively), and the responses of treated patients surpassed those of uninfected adults (SI, 19 and 32, P = .002 and .101, respectively). Unlike the patients in the untreated group, the patients in the treated group mounted a 6-fold increased HIV-1 p24 response (SI increase, 1.0 to 5.7, P = .01) within 3 months. HIV-1-specific cytotoxicity remained detectable in most treated patients. Thus, combination therapy administered within 3-4 months of infection was associated with improved T-cell memory responses that were distinct from those of untreated patients. The amplified HIV-1-specific T- cell responses may help maintain cytotoxic activities.
UR - http://www.scopus.com/inward/record.url?scp=0033966634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033966634&partnerID=8YFLogxK
U2 - 10.1086/315202
DO - 10.1086/315202
M3 - Article
C2 - 10608758
AN - SCOPUS:0033966634
SN - 0022-1899
VL - 181
SP - 121
EP - 131
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -